Name: NTRK gene fusions in solid tumors: IHC and molecular testing strategies
Start: 2021-05-12T15:00:00Z
End: 2021-05-12T15:01:00.000Z
Location: BrightTALK
Rating: 5

This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

En este seminario web de una hora, tres expertos discutirán los desafíos actuales para la determinación de clonalidad en linfomas de células B y cómo el test de sondas de ARNm-ISH dual VENTANA kappa y lambda aborda muchos de estos desafíos.  Los casos serán presentados por hematopatólogos con experiencia práctica con este test dual.  Este seminario web se impartirá en español y estará dirigido a patólogos de varios países europeos y latinoamericanos.

Revolucionando la hematopatología: Papel del test dual de ARNm ISH ultrasensible para kappa y lambda

Roche Diagnostics hosted a satellite symposium at the 22nd scientific meeting of the European Association of Hematopathology on September 24, 2024.  In this recorded session, the speakers presented current challenges with methods used to determine clonality in B-cell malignancies and described the benefits and limitations of a newly available ultrasensitive kappa and lambda dual ISH mRNA assay in light chain restriction.

Revolutionizing Hematopathology:The Role of an Ultrasensitive Kappa & Lambda Dual ISH mRNA assay

Note: This webinar will be presented in Spanish, with slides prepared in English.
In this webinar Dr. Manuel Rodriguez-Justo will present on DNA Mismatch Repair (MMR) protein expression and how it is a key biomarker in cancer for determining genetic risk for Lynch syndrome and eligibility for immunotherapy. This webinar will explore implementation of MMR immunohistochemistry and Microsatellite Instability (MSI) molecular testing to highlight their clinical impact and discuss best practices in a clinical setting.

MMR/MSI testing in solid tumors: testing landscape and best practice

Join us to learn about how you can bring a ctDNA based non-Hodgkin lymphoma research assay for minimal residual disease monitoring and molecular profiling research to your lab. This webinar will be presented by Piers Blombery, MBBS, PhD, with Peter Mac and Alexandra Markus, PharmD, with Roche Diagnostics Solutions.

Liquid biopsy in non-Hodgkin lymphoma: New tools to advance research in the lab

Immunohistochemistry assessment of PD-L1 protein expression levels in the tumor microenvironment is critical for identifying patients eligible for immunotherapy. Currently, different scoring approaches are used to assess tumor cell and immune cell staining with each approach having unique challenges. This talk presents the Tumor Area Positivity (TAP) score, a simple, visual-based estimate scoring algorithm that combines tumor cells and immune cells to identify PD-L1 levels. Samples were stained using the VENTANA PD-L1 (SP263) Assay.

Tumor Area Positivity (TAP): a novel scoring algorithm for PD-L1 assessment

In this webinar, Drs. Hicks and Badve will discuss the latest advances in HER2 immunohistochemical testing and interpretation, with a focus on the emerging category of "HER2-Low" patients who show favorable responses to the new antibody drug conjugate trastuzumab deruxtecan (ENHERTU®). They will emphasize results from the pivotal DESTINY-Breast04 trial and their implications for accurate determination of HER2 status as a basis of therapy selection for breast cancer patients.

HER2-Low: a new category of patients who benefit from HER2-targeted therapy

If you missed the opportunity at the European Congress of Pathology 2022 Roche DP symposium, take your chance now. Learn how Digital AI algorithms in pathology already improves patient‘s outcome, enhance drug development and unfolds unknown features of importance in morphology, developing our basic understanding of pathology. Listen to how an open integrated platform approach will enable pathologists to access and build the optimal portfolio of algorithms from different providers.

Unlocking the future of digital pathology: open environment is the Key!

In this webinar, Dr. Walk will discuss how PathAI aims to improve cancer patient outcomes using the power of Artificial Intelligence, the importance of the PD-L1 tissue biomarker in immuno-oncology, and the deployment of the PathAI PD-L1 (28-8) image analysis algorithm bundle on the Roche navify Digital Pathology open environment.  The webinar will include a live demonstration of user workflow of the algorithm on relevant whole slide images of stained cancer tissues, illustrating the advantages of PD-L1 quantitation.

PathAI PD-L1(28-8)integration on Roche navify Digital Pathology open environment

This webinar, sponsored by Roche, provided valuable insights into the latest advances in HER2 diagnostics in breast cancer. Dr. Sangeeta Desai, Professor and Head at the Department of Pathology, Tata Memorial Centre, India a renowned expert with over three decades of experience and more than 250 research papers published, shared her knowledge on the HER2 FISH vs DISH assay and its crucial role in patient management. 
In addition, a panel discussion featuring Dr. Suseela Kodandapani and Dr. Veena R, along with Dr. Desai, provided a platform for the experts to discuss various unresolved issues and controversies in breast cancer diagnosis. Attendees also had the opportunity to participate in an open question session.
The event was a great success, with over 400 registrations and 188 attending the live webinar. We extend our gratitude to our colleagues in the Indian affiliate, for organizing this insightful webinar.
If you were unable to join on March 16, 2023, we invite you to take advantage of the opportunity to watch the recording and learn from the esteemed experts who participated in this event.

HER2 Testing: Towards a Brighter Future

(Note: This webinar will be presented in Japanese.) In this webinar, our speakers will discuss mechanisms and clinical evaluation of DNA mismatch repair (MMR) status in solid tumor oncology. Speakers will present case studies, and share clinical experience using MMR immunohistochemistry in the context of cancer immunotherapy.

Dr. Kuwata is Chief of the Department of Genetic Medicine & Services at National Cancer Center Hospital East in Chiba, Japan. As a leading pathologist and established investigator, Dr. Kuwata has been active in the field for 27 years, serving on multiple national professional committees and is a key author of pathology and cancer guidelines in Japan with over 100 peer-reviewed publications. Dr. Kawazoe is a staff physician in the Department of Gastrointestinal Oncology at National Cancer Center Hospital East and an established investigator, who has been active in the field for 9 years with active translational research programs on cancer biomarkers and therapy with 48 peer-reviewed publications.

固形がんにおけるDNAミスマッチ修復(MMR) 機能異常とその臨床的意義 〜IHC検査とがん免疫療法の臨床事例を踏まえて〜

This webinar will share compelling research that evaluated the cost-effectiveness of
PD-L1 testing with an in vitro diagnostic (IVD) compared to a laboratory-developed test
(LDT) for allocating patients with non-small cell lung cancer (NSCLC) to treatment with
either pembrolizumab or chemotherapy, using the German healthcare system as a
model.

Cost effectiveness analysis of PD-L1 testing in NSCLC - IVD vs LDT

This webinar, sponsored by Roche, aims to provide an understanding of the scientific development and significance of DNA mismatch repair (MMR) deficiency testing in colorectal cancer (CRC), including MMR 
mechanism, the clinical impact of dMMR/MSI determination in CRC, testing methodology and 
case discussion. Dr. Sheng will share perspectives derived from clinical cases and experiences 
related to MMR testing.
Dr. Sheng is a professor and the chief pathologist at Fudan University Shanghai Cancer 
Center. Dr. Sheng is one of China's leading experts in gastrointestinal cancer and malignant 
lymphoma with 20 years of pathology experience. A member of multiple national professional 
committees and a key author on diagnostic guidelines, Dr. Sheng has published over 120
research papers and has been actively involved in multiple clinical trials.

Immunohistochemistry detection of DNA mismatch repair in colorectal cancer

In this webinar, hosted by Roche Diagnostics Solutions, Giuseppe Mallel, MD, Pathologist and Issar Yazbin, VP of Product Management, both from Ibex Medical Analytics Ltd., will discuss the Galen suite of AI digital pathology image analysis algorithms developed by IBEX medical analytics.  Our speakers will review the technology used to develop the Galen image analysis algorithms and present clinical data for these tools.

How Trusted AI Helps Pathologists Transform Cancer Diagnosis

If you missed the opportunity at the European Congress of Pathology 2021 Roche symposium, take your chance now. Prof. Penault-Llorca and Prof. Viale will share their expert opinion through discussion on several questions aiming to reveal controversies and unsolved issues in breast cancer diagnosis and personalized approach (eg. TILs, HER2 low, etc...). It will be followed by the registered question and answer session where participants submitted their questions to the experts.

Dialogue between experts: Controversies and unsolved issues in Breast Cancer

In this webinar, industry thought leader Dr. Philippe Taniere will cover the fundamentals of MMR immunohistochemistry testing, including the colorectal carcinoma (CRC) workflow, potential pitfalls and pre-analytic recommendations. Using case examples, he will share insights on how to handle cases with loss. He will also explore multiplexing with molecular tests as well as the impact of CRC MMR testing on therapeutic outcomes.
Dr. Taniere is a consultant in histopathology at the Queen Elizabeth Hospital and an honorary senior lecturer at the Medical School, Birmingham, United Kingdom, with a special interest in gastrointestinal and pancreatico-biliary pathology. He has served on multiple international committees and advisory boards and is an author on over 100 peer-reviewed publications.

DNA Mismatch Repair System Assessment in Colorectal Adenocarcinoma

This webinar will discuss mechanisms and clinical evaluation of DNA mismatch repair (MMR) status in solid tumor oncology. Speakers will present case studies, and share clinical experience using MMR immunohistochemistry in the context of cancer immunotherapy.

Dr. Kuwata is Chief of the Department of Genetic Medicine & Services at National Cancer Center Hospital East in Chiba, Japan. As a leading pathologist and established investigator, Dr. Kuwata has been active in the field for 27 years, serving on multiple national professional committees and is a key author of pathology and cancer guidelines in Japan with over 100 peer-reviewed publications. Dr. Kawazoe is a staff physician in the Department of Gastrointestinal Oncology at National Cancer Center Hospital East and an established investigator, who has been active in the field for 9 years with active translational research programs on cancer biomarkers and therapy with 48 peer-reviewed publications.

Mismatch Repair Immunohistochemistry in Clinical Oncology

In this webinar, Dr Paolo Ocampo, Pathologist in Data Science Imaging at Genentech/Roche Personalised Healthcare, will explore the immense potential of deep-learning models to improve accuracy, efficiency and reproducibility in the clinical practice of anatomic pathology. Presenting an example from his published work, he will describe a deep-learning strategy that uses scanned whole-slide pathology images and convolutional neural networks to classify lung cancer tumours accurately and predict disease-linked gene mutations in patients with adenocarcinoma. Importantly, Dr Ocampo will discuss the remaining challenges that need to be overcome to unlock the full clinical value of artificial intelligence in pathology.

Deep learning in the pathology lab: balancing the hope and the hype

As pan-TRK IHC evaluation becomes a more integrated part of NTRK testing in clinical practice, take the opportunity to learn from Dr. Lawrence Weiss (US) and Dr. Fernando López-Ríos (Spain), who are internationally-recognized leaders on the topic. They will present selected cases to cover diverse histologies and offer a pragmatic overview of pan-TRK IHC interpretation. Practical tips and tricks for the optimal interpretation of findings will be discussed along with a series of relevant questions from practicing pathologists.

NTRK Testing: Practical Considerations for IHC Interpretation

In this webinar Drs. Marchiò and Büttner will review the role of NTRK gene fusions in solid tumors, with an in-depth look at IHC and molecular methods of testing. Dr. Marchiò will discuss some specific IHC staining examples and how to interpret them; while Dr. Büttner will provide insight on molecular testing considerations with strengths and weaknesses. This webinar will provide an expert look into the NTRK testing landscape with an opportunity for questions and discussion.

NTRK gene fusions in solid tumors: IHC and molecular testing strategies

NTRK

Gene fusions

tumors

The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.

Medical Research

Get powerful life science insights from influential experts. Connect with thought leaders and colleagues to get the most up-to-date knowledge on strategies and initiatives to accelerate the transformation of U.S. and global health care from a volume- to value-based marketplace.

NTRK gene fusions in solid tumors: IHC and molecular testing strategies

Presented by

About this talk

More from this channel